Drägerwerk AG & Co. KGaA/€DRW8
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Drägerwerk AG & Co. KGaA
Drägerwerk AG & Co. KGaA is a German company specializing in medical and safety technology. The company provides a range of products and solutions in the fields of critical care, which includes anesthesia workstations, ventilators, and patient monitoring, as well as safety products for personal protection, gas detection, and firefighting. Dräger was founded in 1889 and is headquartered in Lübeck, Germany. Its operations extend globally, serving various industries such as healthcare, emergency services, mining, and industrial applications. Drägerwerk's strategic strength lies in its focus on high-quality, technologically advanced products and its long-standing expertise in medical and safety technologies.
- Ticker
- €DRW8
- Sector
- Health
- Primary listing
- XETRA
- Employees
- 16,716
- Headquarters
- Lübeck, Germany
- Website
- www.draeger.com
DRW8 Metrics
BasicAdvanced
€1.8B
-
-
0.60
€2.21
2.68%
Price and volume
Market cap
€1.8B
Beta
0.6
52-week high
€88.20
52-week low
€56.40
Average daily volume
5.3K
Dividend rate
€2.21
Financial strength
Current ratio
2.069
Quick ratio
1.129
Long term debt to equity
0.207
Total debt to equity
0.212
Dividend payout ratio (TTM)
24.75%
Interest coverage (TTM)
12.84%
Profitability
EBITDA (TTM)
339.117
Gross margin (TTM)
46.39%
Net profit margin (TTM)
4.72%
Operating margin (TTM)
7.08%
Effective tax rate (TTM)
33.38%
Revenue per employee (TTM)
€210,000
Management effectiveness
Return on assets (TTM)
5.05%
Return on equity (TTM)
10.48%
Valuation
Dividend yield (TTM)
2.68%
Forward dividend yield
2.68%
Growth
Revenue change (TTM)
5.06%
3-year revenue growth (CAGR)
2.47%
10-year revenue growth (CAGR)
3.57%
3-year dividend per share growth (CAGR)
128.61%
10-year dividend per share growth (CAGR)
28.15%
Bulls say / Bears say
In the first nine months of 2026, currency-adjusted orders rose 3.6% and sales grew 5.3%; Dräger also maintained its full-year sales and margin outlook. That gives the growth case support from both demand and deliveries. (Dräger)
Safety Technology is a clear growth engine: nine-month orders rose 13.1%, and management said current defence orders support its ambition to grow defence sales to about €300 million. Stronger performance here could help offset softer medical demand. (Stock Analysis)
The FDA has lifted its warning letter, reopening a path to US patient-monitoring opportunities. Berenberg expects this, alongside operational improvements, to support higher margins and EBIT growth through 2028. (Investing.com, Investing.com)
Third-quarter EBIT fell to €48 million from €56.7 million a year earlier, even with €20.1 million of customs refunds included. Higher operating costs and slower sales growth put pressure on quarterly profitability. (Stock Analysis)
Medical Technology remains a weak spot: nine-month orders fell 3.5%, and the division was still loss-making, with its third-quarter EBIT margin down to 1.0% from 2.3%. This limits how much the group can rely on medical recovery to lift earnings. (Stock Analysis)
Management says China is delivering no growth and remains below expectations. It also warns that Chinese competitors are becoming more aggressive in other markets, which could make it harder for Dräger to win business internationally. (Stock Analysis)
Data summarised monthly by Lightyear AI. Last updated on 11 Nov 2026.
DRW8 Financial Performance
Revenues and expenses
DRW8 Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.